LINC00941 promotes pancreatic cancer malignancy by interacting with ANXA2 and suppressing NEDD4L-mediated degradation of ANXA2

Recently, long non-coding RNAs (lncRNA) have been proven to regulate pancreatic Cancer (PC) progression. We aimed to explore the pathogenesis of LINC00941 in PC regarding protein binding. By using PCR analysis, we found that LINC00941 was overexpressed in PC tissues and was higher in patients with liver metastasis than in patients without liver metastasis. In addition, high LINC00941 expression was associated with a poor prognosis. Functional experiments and mice models were respectively used to evaluate PC cell proliferation and migration in vitro and in vivo. The results suggested that LINC00941 overexpression promoted PC proliferation and metastasis. Subsequently, RNA pull-down, mass spectrometry (MS), and RNA-binding protein immunoprecipitation (RIP) were performed to identify LINC00941-interacting proteins. The results suggested that AnxA2 was the potential LINC00941-interacting protein. Nucleotides 500-1390 of LINC00941 could bind to the Annexin 1 domain of AnxA2. LINC00941-mediated malignant phenotype of PC was reversed by AnxA2 depletion. Co-immunoprecipitation (Co-IP) followed by MS was conducted to determine the potential interacting protein of LINC00941. The results illustrated that NEDD4L, an E3 Ligase involved in ubiquitin-mediated protein degradation, bound to the Annexin 1 domain of AnxA2 and promoted its degradation. Mechanically, LINC00941 functioned as a decoy to bind to AnxA2 and suppressed its degradation by enclosing the domain that binds to NEDD4L. Eventually, LINC00941 upregulated AnxA2 and activated FAK/Akt signaling, increasing PC cell proliferation and metastasis. This study indicates that LINC00941 promotes PC proliferation and metastasis by binding AnxA2 and potentiating its stability, leading to the activation of FAK/Akt signaling. Our data demonstrate that LINC00941 may serve as a novel target for prognosis and therapy.